Insomnia Management in Patients with Grief and Substance Abuse History

Medication Selection

• The American Academy of Sleep Medicine recommends ramelteon for patients with substance use history because it works through melatonin receptors, eliminating dependence risk entirely 1, 2
• Ramelteon is the only FDA-approved sleep medication with no controlled substance scheduling 1, 2
• The American Academy of Sleep Medicine suggests doxepin 3-6 mg for sleep maintenance insomnia if ramelteon proves insufficient, due to its low addiction potential and minimal anticholinergic effects 1, 3

Non-Pharmacologic Treatment

• Cognitive Behavioral Therapy for Insomnia (CBT-I) must be initiated alongside any medication, as it provides superior long-term outcomes and addresses underlying mechanisms 1, 2, 3
• CBT-I components include stimulus control therapy, sleep restriction therapy, cognitive restructuring, and relaxation training 2

Medications to Avoid

• Traditional benzodiazepines should be avoided entirely due to high dependence potential, severe withdrawal syndromes, and cognitive impairment 1, 2
• Trazodone is explicitly not recommended by the American Academy of Sleep Medicine for insomnia due to cardiac risks and lack of efficacy data 2, 3
• Over-the-counter antihistamines should be discouraged due to lack of efficacy data, strong anticholinergic effects, and daytime sedation 1, 2, 3

Implementation Strategy

• Start ramelteon 8 mg at bedtime for sleep onset difficulties and simultaneously initiate CBT-I 1, 3
• Reassess after 1-2 weeks to evaluate efficacy on sleep latency, total sleep time, and daytime functioning 1
• Monitor for adverse effects, including morning sedation and complex sleep behaviors 1

Critical Monitoring Requirements

• Maintain sleep logs to track improvement objectively 1